Viewpoint - Role of supplements in joint health

Should GPs consider supplements for patients with musculoskeletal symptoms? By Dr Rod Hughes

Studies failed to show glucosamine improved pain in osteoarthritis (Photograph: SPL)

The attempted relief of acute and chronic pain due to musculoskeletal conditions, such as soft tissue injury, osteoarthritis (OA) and inflammatory synovitis, occupies a significant proportion of the workload in general practice.

While administration of simple analgesics and NSAIDs can be reassuring and effective, both groups of medicines are often accompanied by adverse effects, such as constipation and headache with some analgesics and dyspepsia and peptic ulceration with NSAIDs. These side-effects can result in non-adherence, limitation of dose or duration and, in some cases, lead to overt harm.

As a general rule, patients with musculoskeletal pain find that substances derived from the 'natural world' that are reputed to ease pain and inflammation may be an attractive option.

The clinical evidence
Fish oil, olive oil and omega-3/6 long-chain fatty acids.

Supplements, such as fish oil, olive oil and omega-3/6 long- chain fatty acids have traditionally been considered as reputable antioxidants and anti- inflammatories.

Their use is undoubtedly widespread and their benefits may extend to effects on cholesterol, vitamin supplementation, memory and heart disease but good quality evidence to support their use in musculoskeletal disease is scarce.

Intake of oily fish as part of a regular diet has been shown in a retrospective observational study to decrease the likelihood of developing rheumatoid arthritis.1

Glucosamine and chondroitin
Glucosamine was first marketed in the UK in 1988 and had become firmly established as the market leader in supplements for OA by the late 1990s. Glucosamine and chondroitin are often combined in the same supplement.

A number of initial studies suggested safety and efficacy of this combination supplement in OA pain relief at various sites.

In 2002, the first UK-based RCT of glucosamine sulphate in OA of the knee was published.2 While detecting that glucosamine use was associated with a strong placebo effect of 33%, the study failed to show any marked reduction in pain in patients taking glucosamine.

In perhaps the largest study in the US, the glucosamine/chondroitin arthritis intervention trial, patients with mild to moderate OA did not respond to either glucosamine or chondroitin, while a subset of patients with severe OA experienced some pain relief.3

In 2010, a Swiss group reported an updated meta-analysis of studies of glucosamine and/or chondroitin in OA of the hip and knee.4 They concluded that, for the studies they had analysed, neither glucosamine nor chondroitin conferred any benefit in OA and urged authorities not to cover the cost of these preparations or prescribe them to new patients.

Rosehip extracts
Roses and rosehip extract have a long history of medicinal use. The seeds and husks of fruit from a sub-species of rosa canina have been found to contain substances that include an anti-inflammatory galactolipid (known as GOPO) that is heat and light sensitive.

It can only be fully preserved by extraction processes that operate at low temperatures and in low light levels. It is claimed that GOPO is an anti-inflammatory (reducing CRP levels in healthy volunteers) and that it leads to reduced chemotaxis in neutrophils.5

Claims of efficacy in symptom relief for musculoskeletal conditions are based on a number of good quality studies with sound methodology, performed on patients with OA or rheumatoid arthritis by researchers from Scandinavia and Germany.

Supplements containing GOPO have been shown to improve both inflammatory disease activity and patient reported functional outcome in rheumatoid arthritis,6 symptoms of pain and stiffness in OA7 and acute exacerbations of chronic back pain.8

In a meta-analysis of trials of rosehip extracts of various types in OA published in 2008, the authors concluded that there was good evidence of efficacy for rosehip extracts.9 These claims have been supported and enhanced by the results of further studies since that meta-analysis.6

It is still unclear whether standard preparations of rosehip extract prepared under less stringent conditions share the same GOPO concentrations or indeed efficacy.

Pain relief
There is some clinical evidence to support the efficacy (and probable safety) of a small number of nutritional supplements for symptom relief in OA, rheumatoid arthritis and musculoskeletal pain (for example, rosehip extracts).

While no supplement has been proven to be substantially better at relieving pain than conventional analgesics and NSAIDs, supplements may be safer to take than NSAIDs. They might be more acceptable to patients for long-term use and may be accompanied by powerful placebo effects.2 Indeed supplement use can lead to a reduced need for conventional analgesics and NSAIDs.

With the available evidence, and if included as part of a self- management package for musculoskeletal pain, it is my belief that there is no justification for dietary supplements to be available on prescription.

They should be available OTC with packaging reflecting reasonable claims for safety and efficacy and patients should use them for a trial period of three months.

This will be long enough to detect any symptomatic benefit but may not be long enough to get disease modification in OA. Consumers should be encouraged to have reasonable expectations, and indeed reasonable doubts, about efficacy.

Lifestyle advice
When consulted on possible supplement use, it would be reasonable for GPs to advise patients according to the available evidence, while suggesting that patients use supplements complementary to more traditional medicines.

Patients with musculoskeletal pain maximise their chances of relief if they also adhere to appropriate lifestyle advice, such as controlling excess body weight and protecting damaged joints.

  • Dr Hughes is a consultant rheumatologist at St Peter's Hospital, Surrey.
  • Dr Hughes has previously provided paid consultancy work on Litozin (rosehip extract) for Spink PR.

1. Rosell M, Wesley AM, Rydin K et al. Epidemiology 2009; 20: 896-901.

2. Hughes R, Carr A. Rheumatol 2002; 41: 279-84.

3. Sawitzke AD, Shi H, Finco MF et al. Ann Rheum Dis 2010; 69(8): 1459-64.

4. Wandel S, Juni P, Tendal B et al. BMJ 2010; 341: c4675.

5. Larsen E, Kharazmi A, Christensen LP et al. J Nat Prod 2003; 66: 994-5.

6. Willich SN, Rossnagel K, Roll S et al. Phytomedicine 2010; 17: 87-93.

7. Winther SN, Apel K, Thornsborg GA. Scand J Rheumatol 2005; 34: 302-8.

8. Chrubasik C, Wiesner L, Black A et al. Phytotherapy Research 2008; 22: 1141-8.

9. Christensen R, Bartels EM, Altman RD et al. Osteoarthritis Cartilage 2008; 16: 965-72.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins


Already registered?

Sign in

Just published

Young doctor

BMA poll could see 'demeaning' junior doctor title ditched

The BMA could drop the term 'junior doctor' in favour of 'resident doctor' to better...

Houses of parliament

Tory peer calls PA fears 'Luddism' and claims most GP visits 'incredibly straightforward'

Most GP appointments are 'incredibly straightforward' and fears over a wider role...

UK money

NHS pension contribution overhaul to go ahead from April

Changes to NHS pension contribution rates, which will see the top earners required...

BMA sign

BMA warns £800m lost from GP contract since 2019 as last-ditch talks continue

BMA negotiators remain in talks over an improved GP contract offer for 2024/25 just...

GP consultation

GPs still under pressure to prescribe black triangle drug inclisiran

GPs are continuing to face pressure to prescribe the black triangle drug inclisiran...

BMA chair Professor Phil Banfield

Lords urged to block legislation for GMC to regulate PAs

The BMA has urged peers to block legislation that would make the GMC responsible...